Study met its primary endpoint and showed significant and clinically meaningful improvements in multiple symptoms of Contact Lens Discomfort and signs of concomitant Meibomian Gland Dysfunction
Robust safety and efficacy data supports advancing AZR-MD-001 into Phase 3 clinical trials TEL AVIV, Israel (BUSINESS WIRE) Azura Ophthalmics Ltd., a clinical-stage biopharmaceutical company developing a new therapeutic class of Ophthalmic Keratolytics for ocular surface diseases, today announced multiple pre.
TEL AVIV, Israel & MELBOURNE, Australia (BUSINESS WIRE) Azura Ophthalmics Ltd., a clinical-stage biopharmaceutical company developing a new therapeutic class of Ophthalmic Keratolytics for ocular surface diseases, today announced that positive 3-month efficacy and safety results from its Phase 2b study of AZR-MD-0.
Azura Ophthalmics Expands Broad Intellectual Property Portfolio to 12 U S and European Patents streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.